SCHEMBL6901540

SCHEMBL6901540

CCC(=O)NC(=O)CNc1ccc(O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
UBE2N P61088 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 7/20 0.43
MAPT P10636 7/20 0.43
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
HPGD P15428 3/20 0.43
ALOX15 P16050 3/20 0.43
MAPK1 P28482 3/20 0.43
POLB P06746 2/20 0.43
CASP1 P29466 2/20 0.43
BLM P54132 2/20 0.43
HSD17B10 Q99714 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
APAF1 O14727 1/20 0.43
USP2 O75604 1/20 0.43
ALOX12 P18054 1/20 0.43
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6908850 0.84 GAA (0.51) ALDH1A1SMN1; SMN2GAAMAPTKMT2A
SCHEMBL6905877 0.84 MAPT (0.52) ALDH1A1GAAMAPTKMT2AMEN1
SCHEMBL6907375 0.80 ALDH1A1 (0.47) ALDH1A1GAAMAPTKMT2AMEN1
SCHEMBL3660127 0.80 CA1 (0.44) ALDH1A1GAAMAPTKMT2AMEN1
SCHEMBL10031657 0.79 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2GAAMAPTKMT2A
SCHEMBL8621971 0.79 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2GAAMAPTKMT2A
SCHEMBL6907646 0.79 MAPT (0.47) ALDH1A1SMN1; SMN2GAAMAPTKMT2A
SCHEMBL4929584 0.76 MIF (0.44) ALDH1A1GAAMAPTKMT2AMEN1
SCHEMBL21747434 0.76 ALDH1A1 (0.50) ALDH1A1GAAMAPTKMT2AMEN1
Parapropamol SCHEMBL1064972 0.75 MAPT (0.63) ALDH1A1SMN1; SMN2GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 ALDH1A1 1110/4885UBE2N 2766/4885SMN1; SMN2 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.